Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP), a biomarker of left ventricular dysfunction

Hemodialysis International

Volumn 10, Issue 4, 2006, Pages 394-398

  Odar Cederlöf, Ingegerd ^a   Bjellerup, Per ^a   Williams, Amy ^b   Blagg, Christopher R ^c,d   Twardowski, Zbylut ^e   Ting, George ^f   Kjellstrand, Carl M ^g  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b MAYO CLINIC   (United States)

^c Northwest Kidney Centers   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e UNIVERSITY OF MISSOURI   (United States)

^f EL CAMINO HOSPITAL   (United States)

^g Aksys Ltd   (United States)

Author keywords

Brain natriuretic peptide (BNP); Daily dialysis; Heart failure; Hemodialysis; Kidney failure

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; IMMUNORADIOMETRIC ASSAY; KIDNEY POLYCYSTIC DISEASE; MALE; PROTEIN BLOOD LEVEL; RENOVASCULAR DISEASE;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; RENAL DIALYSIS; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 33749344172     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2006.00136.x     Document Type: Article

References (25)

1. Morbidity and mortality: USRDS 2005 Annual Data Report. Am J Kidney Dis. 2006; 47 (Suppl 1): S121-S144.
2. Foley RN, Parfrey PS, Sarnak MY. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(Suppl 3): S112-S119.
3. Mark DB, Felker GM. B-type natriuretic peptide - a biomarker for all seasons? N Engl J Med. 2004; 350: 718-720.
4. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest. 1991; 87: 1402-1412.
5. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain natriuretic peptide as an indicator for angiotension-converting enzyme inhibition after myocardial infarction. Lancet. 1993; 341: 1109-1113.
6. Cowie MR, Struthers AD, Wood DA, et al. Value of natriuretic peptides in assessment of patients with possible heart failure in primary care. Lancet. 1997; 350: 1349-1353.
7. Dries DL, Stevenson LW. Brain natriuretic peptide as bridge to therapy for heart failure. Lancet. 2000; 355: 1112-1113.
8. Maisel AS, Koon J, Krishnaswamy P, et al. Utility of B-natriuretic peptide as a rapid point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J. 2001; 141: 367-374.
9. Maisel AS, Krishnaswamy P, Nowak RM, et al. Breathing not properly multinational study investigators: Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002; 347: 161-167.
10. Lang CC, Choy AM, Henderson IS, Coutie WJ, Struthers AD. Effect of hemodialysis on plasma levels of brain natriuretic peptide in patients with chronic renal failure. Clin Sci. 1992; 82: 127-131.
11. Ishizaka Y, Yamamoto Y, Fukunaga T, et al. Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis. 1994; 24: 461-472.
12. Nitta K, Kawashima A, Yumura W, et al. Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol. 1998; 18: 411-415.
13. Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 1997; 96: 509-516.
14. De Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001; 345: 1014-1021.
15. Naganuma T, Sugimura K, Wada S, et al. The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol. 2002; 22: 437-444.
16. Zoccali C, Mallamaci F, Benedetto FA, et al. Creed investigators: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol. 2001; 12: 1508-1515.
17. Levin ER, Garnder DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998; 339: 321-328.
18. Odar-Cederlof I, Kjellstrand CM. Cardiovasoactive peptides in hemodialysis patients: Diagnostic tools and predictors of outcome. A review of present knowledge and future directions. Hemodial Int. 2003; 7: 222-231.
19. McDonagh TA, Cunningham AD, Morrison CE, et al. Left ventricular dysfunction, natriuretic peptides and mortality in an urban population. Heart. 2001; 86: 21-26.
20. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004; 350: 655-663.
21. Troughton RW, Frampton CM, Yandie TG, Espiner EA, Nicholis MG, Richards AM. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000; 355: 1126-1130.
22. Ayus JC, Mizani MR, Achinger SG, Thadhani R, Go AS, Lee S. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: A prospective, controlled study. J Am Soc Nephrol. 2005; 16: 2778-2788.
23. Chan C, Floras JS, Miller JA, Pierratos A. Improvement in ejection fraction by nocturnal hemodialysis in end-stage renal failure patients with coexisting heart failure. Nephrol Dial Transplant. 2002; 17: 1518-1521.
24. Odar-Cederlöf I, Ericsson F, Theodorson E, Kjellstrand C. Neuropeptide Y and atrial natriuretic peptide as prognostic markers in hemodialysis patients. ASAIO J. 2003; 49: 74-80.
25. MaKie PM, Burnett JC, Jr. B-type natriuretic peptide as a biomarker beyond heart failure: Speculations and opportunities. Mayo Clin Proc. 2005; 80: 1029-36.